Curis, Inc. (NASDAQ:CRIS) is expected to report second quarter earnings results, after market close, on Tuesday 4th August 2020.
Analysts polled by Thomson Reuters anticipate second quarter loss of $ 0.19 per share from revenue of $ 2.63 million.
Looking ahead, the full year loss are expected at $ 0.74 per share on the revenues of $ 10.89 million.
Previous Quarter Performance
Curis, Inc. recorded loss for the first quarter of $ 0.28 per share, from the revenue of $ 2.71 million. The quarterly earnings swell 126.67 percent compared with the same quarter last year. According to street consensus, revenue of $ 2.40 million was expected for the first quarter The bottom line results street analysts by $ 0.12 or , at the same time, top line results outshined analysts by $ 0.31 million or 12.92 percent.
Historical Earnings Performance
wpDataChart with provided ID not found! wpDataTable with provided ID not found!Click Here For More Historical Earnings Of Curis, Inc.
Stock Performance
According to the previous trading day, closing price of CRIS was $ 1.19, representing a 91.94 % increase from the 52 week low of $ 0.62 and a 66.85 % decrease over the 52 week high of $ 3.59.
The company has a market capital of $ 43.53 million and is part of the Healthcare sector and Biotechnology industry.
[stock_market_widget type=”chart” template=”basic” color=”orange” assets=”CRIS” range=”1y” interval=”1mo” axes=”true” cursor=”true” api=”yf” style=”height: 400px;”]
Conference Call
Curis, Inc. will be hosting a conference call at 4:30 PM eastern time on 4th August 2020, to discuss its 2Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.curis.com
Curis, Inc., a biotechnology company, focuses on the development and commercialization of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include CUDC-907, an oral dual inhibitor of HDAC and PI3K enzymes, which is in Phase II clinical trial for the treatment of patients with MYC-altered diffuse large B-cell lymphoma and solid tumors; CA-170, an oral small molecule drug candidate that is in Phase I clinical trial for treating patients with advanced solid tumors and lymphomas; CA-4948, an oral small molecule drug candidate, which is in Phase I clinical trial for the treatment of non-hodgkin lymphomas; and CA-327, an oral small molecule drug candidate that is in preclinical stage for the treatment of cancers. The company has collaboration agreement with F.
